Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US-2017362573-A1 · Dec 21, 2017 · US
Systems and methods for growth of intestinal cells in microfluidic devices
US2024254449A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024254449-A1 |
| Application number | US-202418626855-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 4, 2024 |
| Priority date | Feb 1, 2016 |
| Publication date | Aug 1, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
First claim
Opening claim text (preview).
1 - 38 . (canceled) 39 . A method of culturing cells, comprising: a) providing i) induced pluripotent stern cell-derived (iPSC-derived) foregut organoids and ii) a fluidic device comprising a membrane, said membrane comprising a top surface and a bottom surface; b) seeding said iPSC-derived foregut organoids onto said top or bottom surface in the presence of epidermal growth factor (EGF) so as to create seeded organoids, said EGF at an initial concentration in media; and c) decreasing said initial EGF concentration in said media gradually over days to induce differentiation and maturation of foregut epithelium. 40 . The method of claim 39 , wherein said seeded organoids of step b) are cultured under flow conditions. 41 . The method of claim 40 , wherein the culturing under flow conditions results in greater ghrelin secretion as compared to no flow conditions. 42 . The method of claim 39 , where said iPSC-derived foregut organoids of step a) were selected using a selection reagent.
Assignees
Inventors
Classifications
Small molecules not provided for elsewhere · CPC title
Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins · CPC title
Cells of the nervous system · CPC title
involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025) · CPC title
Tumour necrosing factors [TNF] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024254449A1 cover?
- Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allow…
- Who is the assignee on this patent?
- Emulate Inc, Cedars Sinai Medical Center
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0679. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Aug 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).